印度南部成人真菌性角膜炎患者抗真菌耐药模式:3项随机临床试验的事后分析
该事后分析基于印度南部3项随机临床试验(MUTT I、MUTT II、CLAIR)的651例涂片阳性真菌性角膜溃疡患者,从角膜培养中测定那他霉素和伏立康唑的最小抑菌浓度(MIC)。结果显示,真菌分离株对伏立康唑的耐药性总体每年增加1.02倍(95%CI 1.00-1.04;P=0.06),对那他霉素的耐药性总体每年增加1.06倍(95%CI 1.03-1.09;P<0.001)。作者认为,过去十年印度南部对那他霉素和伏立康唑的敏感性可能正在下降,需进一步研究确认并确定其可推广性。
要点
- 真菌分离株对伏立康唑的耐药性总体每年增加1.02倍(95%CI 1.00-1.04;P=0.06)。
- 镰刀菌属对伏立康唑的耐药性每年增加1.04倍(95%CI 1.00-1.06;P=0.01)。
- 真菌分离株对那他霉素的耐药性总体每年增加1.06倍(95%CI 1.03-1.09;P<0.001)。
核心结论
- 该事后分析提示,过去十年印度南部对那他霉素和伏立康唑的敏感性可能正在下降。
- 耐药性增加的趋势可能影响真菌感染的治疗,尤其是感染性真菌性角膜炎,但需进一步研究确认这些发现并确定其可推广性。
研究设计与样本
- 对3项随机临床试验(MUTT I:2010至2011年;MUTT II:2010至2015年;CLAIR:2016至2018年)进行事后分析。
- 纳入印度南部Aravind眼科医院(马杜赖、哥印拜陀、本地治里和蒂鲁内尔维利)连续就诊的18岁及以上涂片阳性真菌性角膜溃疡患者。
- 共获得来自651例患者的890株真菌分离株,其中446例患者的522份样本有MIC数据。
- 采用临床和实验室标准协会(CLSI)标准化方法从角膜培养中测定那他霉素和伏立康唑的MIC。
主要发现
- 真菌分离株总体对伏立康唑的耐药性每年增加1.02倍(95%CI 1.00-1.04;P=0.06)。
- 镰刀菌属对伏立康唑的耐药性每年增加1.04倍(95%CI 1.00-1.06;P=0.01)。
- 真菌分离株总体对那他霉素的耐药性每年增加1.06倍(95%CI 1.03-1.09;P<0.001)。
- 镰刀菌属对那他霉素的耐药性每年增加1.06倍(95%CI 1.05-1.08;P<0.001)。
- 曲霉属对那他霉素的耐药性每年增加1.09倍(95%CI 1.05-1.15;P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步研究确认这些发现并确定其可推广性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Antifungal resistance has been shown to impact treatment success, but research analyzing antifungal resistance is scarce. OBJECTIVE: To evaluate changes in antifungal resistance over time. DESIGN, SETTING, AND PARTICIPANTS: Ad hoc analysis of 3 randomized clinical trials including consecutive patients 18 years and older presenting with smear-positive fungal ulcers to Aravind Eye Hospitals in Madurai, Coimbatore, Pondicherry, and Tirunelveli in South India who participated in 1 of 3 clinical trials: the Mycotic Ulcer Treatment Trials (MUTT) I (2010 to 2011) or II (2010 to 2015) or the Cross-Linking Assisted Infection Reduction (CLAIR) trial (2016 to 2018). This post hoc analysis was designed in March 2021 and data were analyzed in May and November 2021. INTERVENTIONS: Minimum inhibitory concentration (MIC) of natamycin and voriconazole was determined from corneal cultures obtained using standardized methods outlined in the Clinical and Laboratory Standards Institute. MAIN OUTCOMES AND MEASURES: The primary outcome of this post hoc analysis was MIC of natamycin and voriconazole. RESULTS: A total of 890 fungal isolates were obtained from 651 patients (mean [SD] age, 49.6 [13.0]; 191 [43.3%] female) from 2010 to 2018. MICs were available for 522 samples in 446 patients. Fungal isolates overall demonstrated a 1.02-fold increase per year in voriconazole resistance as measured by MICs (95% CI, 1.00-1.04; P = .06). In subgroup analyses, Fusarium species demonstrated a 1.04-fold increase in voriconazole resistance per year (95% CI, 1.00-1.06; P = .01). Fungal isolates showed a 1.06-fold increase in natamycin resistance per year overall (95% CI, 1.03-1.09; P < .001). Fusarium species had a 1.06-fold increase in natamycin resistance (95% CI, 1.05-1.08; P < .001), Aspergillus had a 1.09-fold increase in resistance (95% CI, 1.05-1.15; P < .001), and other filamentous fungi had a 1.07-fold increase in resistance to natamycin per year (95% CI, 1.04-1.10; P < .001). CONCLUSIONS AND RELEVANCE: This post hoc analysis suggests that susceptibility to both natamycin and voriconazole may be decreasing over the last decade in South India. While a trend of increasing resistance could impact treatment of mycoses in general and infectious fungal keratitis in particular, further study is needed to confirm these findings and determine their generalizability to other regions of the world. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT00996736 and NCT02570321.
引用
- Prajna NV, Lalitha P, Krishnan T, et al. Patterns of Antifungal Resistance in Adult Patients With Fungal Keratitis in South India: A Post Hoc Analysis of 3 Randomized Clinical Trials. JAMA Ophthalmol. 2022. PMID: 35024776. doi:10.1001/jamaophthalmol.2021.5765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。